Monday, August 16, 2010

FDA Considers Revoking Approval for Avastin for Metastatic Breast Cancer

According to this article in the Washington Post, the FDA is considering revocation of the drug Avastin for metastatic breast cancer. A recent study shows the drug, which costs $8,000 per month, offers no benefit to these patients.

More information

No comments:

Post a Comment